|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GC |
Gene summary for GC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GC | Gene ID | 2638 |
| Gene name | GC vitamin D binding protein | |
| Gene Alias | DBP | |
| Cytomap | 4q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | P02774 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2638 | GC | S41 | Human | Liver | Cirrhotic | 1.46e-05 | -9.54e-01 | -0.0343 |
| 2638 | GC | S42 | Human | Liver | HCC | 7.42e-03 | -4.85e-01 | -0.0103 |
| 2638 | GC | S43 | Human | Liver | Cirrhotic | 6.46e-26 | -4.03e-01 | -0.0187 |
| 2638 | GC | S44 | Human | Liver | HCC | 2.81e-02 | -6.59e-01 | -0.0083 |
| 2638 | GC | HCC1_Meng | Human | Liver | HCC | 4.12e-31 | -1.56e-01 | 0.0246 |
| 2638 | GC | HCC2_Meng | Human | Liver | HCC | 2.71e-67 | -1.43e+00 | 0.0107 |
| 2638 | GC | cirrhotic2 | Human | Liver | Cirrhotic | 7.17e-07 | 2.86e-01 | 0.0201 |
| 2638 | GC | cirrhotic3 | Human | Liver | Cirrhotic | 1.28e-16 | -6.78e-01 | 0.0215 |
| 2638 | GC | p6 | Human | Liver | Cyst | 1.86e-19 | -1.48e+00 | -0.0218 |
| 2638 | GC | HCC1 | Human | Liver | HCC | 8.30e-06 | 3.63e+00 | 0.5336 |
| 2638 | GC | HCC2 | Human | Liver | HCC | 2.81e-27 | 6.74e+00 | 0.5341 |
| 2638 | GC | HCC5 | Human | Liver | HCC | 7.54e-16 | 3.23e+00 | 0.4932 |
| 2638 | GC | Pt13.a | Human | Liver | HCC | 2.71e-17 | -3.89e-01 | 0.021 |
| 2638 | GC | Pt13.b | Human | Liver | HCC | 6.04e-34 | -4.40e-01 | 0.0251 |
| 2638 | GC | Pt13.c | Human | Liver | HCC | 6.46e-04 | -5.40e-01 | 0.0076 |
| 2638 | GC | Pt14.a | Human | Liver | HCC | 2.30e-04 | -5.47e-01 | 0.0169 |
| 2638 | GC | Pt14.b | Human | Liver | HCC | 2.36e-08 | -3.18e-01 | 0.018 |
| 2638 | GC | Pt14.c | Human | Liver | HCC | 7.42e-04 | -7.82e-01 | 0.0054 |
| 2638 | GC | Pt14.d | Human | Liver | HCC | 1.58e-08 | -4.24e-01 | 0.0143 |
| 2638 | GC | S014 | Human | Liver | HCC | 2.61e-43 | -5.95e-01 | 0.2254 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
| GO:004860823 | Oral cavity | EOLP | reproductive structure development | 80/2218 | 424/18723 | 1.51e-05 | 2.50e-04 | 80 |
| GO:00070202 | Oral cavity | EOLP | microtubule nucleation | 14/2218 | 35/18723 | 2.11e-05 | 3.28e-04 | 14 |
| GO:009730525 | Oral cavity | EOLP | response to alcohol | 53/2218 | 253/18723 | 2.31e-05 | 3.50e-04 | 53 |
| GO:007086121 | Oral cavity | EOLP | regulation of protein exit from endoplasmic reticulum | 12/2218 | 27/18723 | 2.32e-05 | 3.50e-04 | 12 |
| GO:000854424 | Oral cavity | EOLP | epidermis development | 64/2218 | 324/18723 | 2.48e-05 | 3.68e-04 | 64 |
| GO:000703014 | Oral cavity | EOLP | Golgi organization | 37/2218 | 157/18723 | 2.83e-05 | 4.12e-04 | 37 |
| GO:000703422 | Oral cavity | EOLP | vacuolar transport | 36/2218 | 157/18723 | 6.66e-05 | 8.27e-04 | 36 |
| GO:004678521 | Oral cavity | EOLP | microtubule polymerization | 23/2218 | 83/18723 | 6.67e-05 | 8.27e-04 | 23 |
| GO:007266613 | Oral cavity | EOLP | establishment of protein localization to vacuole | 16/2218 | 49/18723 | 1.03e-04 | 1.17e-03 | 16 |
| GO:003021621 | Oral cavity | EOLP | keratinocyte differentiation | 32/2218 | 139/18723 | 1.52e-04 | 1.62e-03 | 32 |
| GO:000662314 | Oral cavity | EOLP | protein targeting to vacuole | 13/2218 | 37/18723 | 1.98e-04 | 2.00e-03 | 13 |
| GO:007266522 | Oral cavity | EOLP | protein localization to vacuole | 19/2218 | 67/18723 | 2.01e-04 | 2.02e-03 | 19 |
| GO:004873224 | Oral cavity | EOLP | gland development | 77/2218 | 436/18723 | 2.05e-04 | 2.06e-03 | 77 |
| GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
| GO:003406722 | Oral cavity | EOLP | protein localization to Golgi apparatus | 11/2218 | 29/18723 | 2.83e-04 | 2.70e-03 | 11 |
| GO:009016111 | Oral cavity | EOLP | Golgi ribbon formation | 7/2218 | 13/18723 | 2.90e-04 | 2.74e-03 | 7 |
| GO:000704122 | Oral cavity | EOLP | lysosomal transport | 27/2218 | 114/18723 | 2.97e-04 | 2.79e-03 | 27 |
| GO:001619722 | Oral cavity | EOLP | endosomal transport | 45/2218 | 230/18723 | 4.63e-04 | 4.07e-03 | 45 |
| GO:003112213 | Oral cavity | EOLP | cytoplasmic microtubule organization | 16/2218 | 56/18723 | 5.70e-04 | 4.82e-03 | 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GC | SNV | Missense_Mutation | c.1096A>G | p.Thr366Ala | p.T366A | P02774 | protein_coding | tolerated(0.35) | benign(0.093) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GC | SNV | Missense_Mutation | novel | c.1236G>T | p.Lys412Asn | p.K412N | P02774 | protein_coding | tolerated(0.22) | benign(0.04) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| GC | insertion | Frame_Shift_Ins | novel | c.41_42insTA | p.Arg14SerfsTer8 | p.R14Sfs*8 | P02774 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GC | insertion | Nonsense_Mutation | novel | c.40_41insACATTTATTAAGCAGTATTCCATGGAATGGGGAATCAATTA | p.Arg14AsnfsTer4 | p.R14Nfs*4 | P02774 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GC | SNV | Missense_Mutation | c.1112G>A | p.Arg371Lys | p.R371K | P02774 | protein_coding | deleterious(0.02) | benign(0.333) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| GC | SNV | Missense_Mutation | c.858G>T | p.Glu286Asp | p.E286D | P02774 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| GC | SNV | Missense_Mutation | c.860N>T | p.Ser287Phe | p.S287F | P02774 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GC | SNV | Missense_Mutation | c.818N>A | p.Leu273Gln | p.L273Q | P02774 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AU-3779-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GC | SNV | Missense_Mutation | c.356C>A | p.Ser119Tyr | p.S119Y | P02774 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| GC | SNV | Missense_Mutation | rs746394990 | c.295G>C | p.Asp99His | p.D99H | P02774 | protein_coding | deleterious(0.02) | possibly_damaging(0.9) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2638 | GC | DRUGGABLE GENOME | inhibitor | CHEMBL712 | ANISINDIONE | |
| 2638 | GC | DRUGGABLE GENOME | cetuximab | CETUXIMAB | 29208668 | |
| 2638 | GC | DRUGGABLE GENOME | Isosorbide Dinitrate | |||
| 2638 | GC | DRUGGABLE GENOME | VITAMIN D | 761406 | ||
| 2638 | GC | DRUGGABLE GENOME | CHEMBL2105671 | AFEGOSTAT TARTRATE | ||
| 2638 | GC | DRUGGABLE GENOME | bevacizumab | BEVACIZUMAB | 29208668 | |
| 2638 | GC | DRUGGABLE GENOME | Pirsidomine | PIRSIDOMINE | ||
| 2638 | GC | DRUGGABLE GENOME | Erythrityl Tetranitrate | |||
| 2638 | GC | DRUGGABLE GENOME | ASA | ASPIRIN | 17555340 | |
| 2638 | GC | DRUGGABLE GENOME | Nitric Oxide |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |